1. Home
  2. JL vs INDP Comparison

JL vs INDP Comparison

Compare JL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JL
  • INDP
  • Stock Information
  • Founded
  • JL 1985
  • INDP 2000
  • Country
  • JL Hong Kong
  • INDP United States
  • Employees
  • JL N/A
  • INDP N/A
  • Industry
  • JL
  • INDP Biotechnology: Pharmaceutical Preparations
  • Sector
  • JL
  • INDP Health Care
  • Exchange
  • JL NYSE
  • INDP Nasdaq
  • Market Cap
  • JL 10.1M
  • INDP 10.2M
  • IPO Year
  • JL 2024
  • INDP N/A
  • Fundamental
  • Price
  • JL $5.31
  • INDP $0.84
  • Analyst Decision
  • JL
  • INDP Strong Buy
  • Analyst Count
  • JL 0
  • INDP 2
  • Target Price
  • JL N/A
  • INDP $8.50
  • AVG Volume (30 Days)
  • JL 65.3K
  • INDP 25.3K
  • Earning Date
  • JL 07-31-2024
  • INDP 03-12-2025
  • Dividend Yield
  • JL N/A
  • INDP N/A
  • EPS Growth
  • JL N/A
  • INDP N/A
  • EPS
  • JL 0.26
  • INDP N/A
  • Revenue
  • JL $28,378,669.00
  • INDP N/A
  • Revenue This Year
  • JL N/A
  • INDP N/A
  • Revenue Next Year
  • JL N/A
  • INDP N/A
  • P/E Ratio
  • JL $20.50
  • INDP N/A
  • Revenue Growth
  • JL N/A
  • INDP N/A
  • 52 Week Low
  • JL $0.23
  • INDP $0.81
  • 52 Week High
  • JL $29.95
  • INDP $3.10
  • Technical
  • Relative Strength Index (RSI)
  • JL 71.16
  • INDP 39.07
  • Support Level
  • JL $4.53
  • INDP $0.86
  • Resistance Level
  • JL $6.25
  • INDP $1.06
  • Average True Range (ATR)
  • JL 0.59
  • INDP 0.08
  • MACD
  • JL 0.04
  • INDP 0.00
  • Stochastic Oscillator
  • JL 66.78
  • INDP 12.80

About JL J-LONG GROUP LIMITED

J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: